Works matching IS 21938210 AND DT 2024 AND VI 14 AND IP 8
Results: 22
Dupilumab in Patients with Atopic Dermatitis: A Multicentric, Long-Term, Real-World Portuguese Study.
- Published in:
- Dermatology & Therapy, 2024, v. 14, n. 8, p. 2209, doi. 10.1007/s13555-024-01235-8
- By:
- Publication type:
- Article
How Digital Solutions Might Provide a World of New Opportunities for Holistic and Empathic Support of Patients with Hidradenitis Suppurativa.
- Published in:
- Dermatology & Therapy, 2024, v. 14, n. 8, p. 1975, doi. 10.1007/s13555-024-01234-9
- By:
- Publication type:
- Article
Biomarkers in Cutaneous Keratinocyte Carcinomas.
- Published in:
- Dermatology & Therapy, 2024, v. 14, n. 8, p. 2039, doi. 10.1007/s13555-024-01233-w
- By:
- Publication type:
- Article
Bridging the Gap: Comparing Patient-Clinician Views on Treatment Goals and Communication in the Management of Atopic Dermatitis Within the Asia–Pacific Region.
- Published in:
- Dermatology & Therapy, 2024, v. 14, n. 8, p. 2195, doi. 10.1007/s13555-024-01232-x
- By:
- Publication type:
- Article
Clinical Characteristics and Disease Burden of Patients with Moderate-to-Severe Generalized Pustular Psoriasis Flares in Taiwan.
- Published in:
- Dermatology & Therapy, 2024, v. 14, n. 8, p. 2261, doi. 10.1007/s13555-024-01228-7
- By:
- Publication type:
- Article
Treatment of Epidermolysis Bullosa and Future Directions: A Review.
- Published in:
- Dermatology & Therapy, 2024, v. 14, n. 8, p. 2059, doi. 10.1007/s13555-024-01227-8
- By:
- Publication type:
- Article
Patients with Moderate-to-Severe Atopic Dermatitis Maintain Stable Response with No or Minimal Fluctuations with 1 Year of Lebrikizumab Treatment.
- Published in:
- Dermatology & Therapy, 2024, v. 14, n. 8, p. 2249, doi. 10.1007/s13555-024-01226-9
- By:
- Publication type:
- Article
Stable Response and Sustained Improvement of Itch and Sleep Symptoms in Patients with Atopic Dermatitis Treated with Lebrikizumab over 52 Weeks.
- Published in:
- Dermatology & Therapy, 2024, v. 14, n. 8, p. 2171, doi. 10.1007/s13555-024-01225-w
- By:
- Publication type:
- Article
Deucravacitinib Improves Patient-Reported Outcomes in Patients with Moderate to Severe Psoriasis: Results from the Phase 3 Randomized POETYK PSO-1 and PSO-2 Trials.
- Published in:
- Dermatology & Therapy, 2024, v. 14, n. 8, p. 2235, doi. 10.1007/s13555-024-01224-x
- By:
- Publication type:
- Article
Psychometric Evaluation of the Facial and Total Vitiligo Area Scoring Index Instruments in the TRuE-V Phase 3 Studies.
- Published in:
- Dermatology & Therapy, 2024, v. 14, n. 8, p. 2223, doi. 10.1007/s13555-024-01223-y
- By:
- Publication type:
- Article
Discussion of EMA Draft Guideline on Quality and Equivalence of Topical Products Based on Comparison of Approved Mometasone Furoate Drugs.
- Published in:
- Dermatology & Therapy, 2024, v. 14, n. 8, p. 2153, doi. 10.1007/s13555-024-01222-z
- By:
- Publication type:
- Article
Correction: Ixekizumab Demonstrates Rapid and Consistent Efficacy for Patients with Psoriatic Arthritis, Regardless of Psoriasis Severity.
- Published in:
- 2024
- By:
- Publication type:
- Correction Notice
Development of the Cutaneous Dermatomyositis Investigator Global Assessment (CDM-IGA): A De Novo IGA of Cutaneous Manifestations of Dermatomyositis.
- Published in:
- Dermatology & Therapy, 2024, v. 14, n. 8, p. 2127, doi. 10.1007/s13555-024-01220-1
- By:
- Publication type:
- Article
Ruxolitinib Cream in Adolescents/Adults with Atopic Dermatitis Meeting Severity Thresholds for Systemic Therapy: Exploratory Analysis of Pooled Results from Two Phase 3 Studies.
- Published in:
- Dermatology & Therapy, 2024, v. 14, n. 8, p. 2139, doi. 10.1007/s13555-024-01219-8
- By:
- Publication type:
- Article
Association Between Natural Hair Color, Race, and Alopecia.
- Published in:
- Dermatology & Therapy, 2024, v. 14, n. 8, p. 2109, doi. 10.1007/s13555-024-01218-9
- By:
- Publication type:
- Article
The Impact of Lebrikizumab on Vaccine-Induced Immune Responses: Results from a Phase 3 Study in Adult Patients with Moderate-to-Severe Atopic Dermatitis.
- Published in:
- Dermatology & Therapy, 2024, v. 14, n. 8, p. 2181, doi. 10.1007/s13555-024-01217-w
- By:
- Publication type:
- Article
Assessment of the Efficacy and Durability of IncobotulinumtoxinA in the Treatment of the Upper Face in Adult Women.
- Published in:
- Dermatology & Therapy, 2024, v. 14, n. 8, p. 2093, doi. 10.1007/s13555-024-01216-x
- By:
- Publication type:
- Article
Psoriasis and Sleep Disturbance: A US Population-Based Study Using the NHANES Database.
- Published in:
- Dermatology & Therapy, 2024, v. 14, n. 8, p. 2277, doi. 10.1007/s13555-024-01211-2
- By:
- Publication type:
- Article
Certolizumab Pegol for the Treatment of Plaque Psoriasis in Routine Clinical Practice: One-Year Results from the CIMREAL Study.
- Published in:
- Dermatology & Therapy, 2024, v. 14, n. 8, p. 2077, doi. 10.1007/s13555-024-01210-3
- By:
- Publication type:
- Article
Hair Shaft Abnormalities as a Dermoscopic Feature of Mycosis Fungoides: Pilot Results.
- Published in:
- Dermatology & Therapy, 2024, v. 14, n. 8, p. 2119, doi. 10.1007/s13555-024-01206-z
- By:
- Publication type:
- Article
Biologics Versus JAK Inhibitors. Part II: Risk of Infections. A Narrative Review.
- Published in:
- Dermatology & Therapy, 2024, v. 14, n. 8, p. 1983, doi. 10.1007/s13555-024-01203-2
- By:
- Publication type:
- Article
Practical Management of the JAK1 Inhibitor Abrocitinib for Atopic Dermatitis in Clinical Practice: Special Safety Considerations.
- Published in:
- Dermatology & Therapy, 2024, v. 14, n. 8, p. 2285, doi. 10.1007/s13555-024-01200-5
- By:
- Publication type:
- Article